Cantor Fitzgerald initiated coverage of NewAmsterdam Pharma (NAMS) with an Overweight rating and $42 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- Buy Rating Affirmed for NewAmsterdam Pharma: Obicetrapib’s Promising Clinical Profile and Market Potential Highlighted
- Strong Investment Potential for NewAmsterdam Pharma’s Obicetrapib Due to Cardiovascular and Metabolic Benefits
- Buy Rating for NewAmsterdam Pharma: Obicetrapib’s Potential in Cardiovascular Risk Reduction and Revenue Growth
- Strong Financial Position and Promising Cardiovascular Developments Propel NewAmsterdam Pharma’s Growth Potential
- NewAmsterdam Pharma Reports Q1 2025 Financial Results